ClinicalTrials.gg

Program

datopotamab deruxtecan

Also written as “Dato-DXd”, “Datopotamab deruxtecan” and “Datopotamab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Triple Negative Breast Neoplasms · Endometrial Neoplasms · Urinary Bladder Neoplasms, led by 2 companies.

Furthest: phase 3, since Oct 4, 202128 company-led studies, 27 open or runningCo-development: Daiichi Sankyo and AstraZeneca, Jul 2020Next primary completion: Jan 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2020 open or runningphase 3since Oct 4, 2021Oct 25, 2018Jan 11, 2027phase 3 · NCT06417814
Daiichi Sankyo87 open or runningphase 3since Nov 19, 2020Jan 9, 2018Jan 1, 2028phase 1 · NCT03401385

Also a collaborator on its studies: Merck and parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Jan 9, 2018.

  1. Sep 22, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT05555732 · 1,233 enrolled · United States, Argentina, Australia and more
  2. Nov 4, 2022Phase 3 study in Breast NeoplasmsAstraZeneca · NCT05629585 · 1,174 enrolled · United States, Belgium, Brazil and more
  3. Dec 28, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05687266 · 1,350 enrolled · United States, Austria, Brazil and more
  4. Oct 12, 20232 phase 3 studies in Breast NeoplasmsAstraZeneca · NCT06112379, NCT06103864
  5. Apr 2, 20242 phase 3 studies in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06350097, NCT06357533
  6. May 13, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06417814 · 768 enrolled · United States, Australia, Belgium and more
  7. Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06564844 · 25 enrolled · United States, Brazil, Canada and more
  8. Jul 4, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07098338 · 278 planned · United States, Australia, Canada and more
  9. Aug 12, 2025Phase 3 study in Urinary Bladder NeoplasmsDaiichi Sankyo · NCT07129993 · 630 planned · United States, Austria, China and more
  10. Sep 11, 2025Phase 3 study in Breast NeoplasmsAstraZeneca · NCT07205822 · 100 planned · United States, China, France and more
  11. Oct 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT07291037 · 400 planned · United States, Australia, Austria and more
  12. Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellAstraZeneca · NCT07720284 · 915 planned · United States, Australia, Brazil and more
  13. Oct 15, 2026Primary completion moved from 2026-09-30 to 2027-01-11Date moved laterphase 3 · +3 months · NCT06417814
  14. Oct 16, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT07890714 · 268 planned · Taiwan

Ahead

  1. Jan 11, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06417814
  2. Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT06103864
  3. Sep 1, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT05629585
  4. Oct 1, 2027Primary completion: phase 2 study in Endometrial NeoplasmsAstraZeneca · NCT05489211

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) ”NCIt, by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan2RecruitingDaiichi SankyoSep 30, 2029268
NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more3RecruitingAstraZenecaSep 11, 2030915
NCT07291037Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingAstraZenecaJan 29, 2029400
NCT07205822Breast Neoplasms · United States, China, France and more3RecruitingAstraZenecaFeb 2, 2028100
NCT07129993Urinary Bladder Neoplasms · United States, Austria, China and more3RecruitingDaiichi SankyoJun 1, 2029630
NCT07098338Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2RecruitingAstraZenecaApr 6, 2029278
NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more3Active, not recruitingAstraZenecaJul 10, 202625
NCT06417814Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaJan 11, 2027768
NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingAstraZenecaDec 28, 2029675
NCT06350097Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3RecruitingAstraZenecaMar 21, 2028582
NCT06103864Breast Neoplasms · United States, Argentina, Australia and more3RecruitingAstraZenecaJul 28, 2027625
NCT06112379Breast Neoplasms · United States, Australia, Austria and more3Active, not recruitingAstraZenecaNov 20, 20281,902
NCT05687266Carcinoma, Non-Small-Cell Lung · United States, Austria, Brazil and more3Active, not recruitingAstraZenecaNov 1, 20271,350
NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaSep 1, 20271,174
NCT05555732Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingDaiichi SankyoMay 11, 20291,233
NCT05489211Endometrial Neoplasms · United States, Canada, China and more2RecruitingAstraZenecaOct 1, 2027454
NCT05460273Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingAstraZenecaNov 7, 2023119
NCT05374512Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaAug 25, 2025644
NCT05215340Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingDaiichi SankyoMar 4, 2030740
NCT05104866Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaJul 24, 2024732
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingAstraZenecaMay 28, 2030630
NCT04656652Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingDaiichi SankyoMay 10, 2024605
NCT04612751Carcinoma, Non-Small-Cell Lung · United States, Belgium, Italy and more1Active, not recruitingAstraZenecaMay 4, 2026155
NCT04526691Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more1Active, not recruitingDaiichi SankyoApr 14, 2024145
NCT04484142Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedDaiichi SankyoMar 10, 2023137
NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more2Active, not recruitingAstraZenecaMay 6, 2025247
NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more2Active, not recruitingAstraZenecaNov 29, 2024243
NCT03401385Triple Negative Breast Neoplasms · United States, Japan1Active, not recruitingDaiichi SankyoJan 1, 2028890

How it is read

Names in the registry

  • “Dato-DXd”, 12 entries
  • “Datopotamab deruxtecan”, 5 entries
  • “Datopotamab Deruxtecan”, 5 entries
  • “Datopotamab deruxtecan (Dato-DXd)”, 2 entries
  • “Datopotamab Deruxtecan (Dato-DXd)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.